| Prior authorization requirements for proprotein convertase subtilisin/kexin type 9 inhibitors across US private and public payers JA Doshi, JT Puckett, MS Parmacek, DJ Rader Circulation: Cardiovascular Quality and Outcomes 11 (1), e003939, 2018 | 39 | 2018 |
| Treatment utilization patterns of newly initiated oral anticancer agents in a national sample of Medicare beneficiaries JA Doshi, J Jahnke, S Raman, JT Puckett, VT Brown, MA Ward, P Li, ... Journal of Managed Care & Specialty Pharmacy 27 (10), 1457-1468, 2021 | 16 | 2021 |
| Barriers and solutions to improve access for chimeric antigen receptor therapies S Kamal-Bahl, JT Puckett, I Bagchi, E Miller-Sonet, SF Huntington Immunotherapy 14 (9), 741-753, 2022 | 14 | 2022 |
| Omalizumab treatment patterns among patients with asthma in the US Medicare population P Li, A Kavati, JT Puckett, J Jahnke, P Busse, NA Hanania, B Ortiz, ... The Journal of Allergy and Clinical Immunology: In Practice 8 (2), 507-515. e10, 2020 | 14 | 2020 |
| The case for using novel value elements when assessing COVID-19 vaccines and therapeutics S Kamal-Bahl, RJ Willke, JT Puckett, JA Doshi Health Affairs Forefront, 2020 | 9 | 2020 |
| Trends and factors associated with insurer approval of proprotein convertase subtilisin/kexin type 9 inhibitor prescriptions JA Doshi, P Li, JT Puckett, AR Pettit, S Raman, MS Parmacek, DJ Rader Value in Health 23 (2), 209-216, 2020 | 7 | 2020 |
| Real‐world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia SF Huntington, E de Nigris, JT Puckett, S Kamal‐Bahl, M Farooqui, ... Cancer Medicine 13 (2), e6953, 2024 | 5 | 2024 |
| Real-world treatment patterns and outcomes after ibrutinib discontinuation among elderly medicare beneficiaries with chronic lymphocytic leukemia: an observational study SF Huntington, E De Nigris, J Puckett, S Kamal-Bahl, MZH Farooqui, ... Blood 140 (Supplement 1), 7939-7940, 2022 | 4 | 2022 |
| The need for a new patient-centered decision tool for value-based treatment choices in oncology JA Doshi, EM Sonet, JT Puckett, H Glick Health Affairs Forefront, 2018 | 4 | 2018 |
| Impact of Updated Clinical Practice Guidelines on Outpatient Treatment for Clostridioides difficile Infection and Associated Clinical Outcomes ER Dubberke, JT Puckett, EN Obi, S Kamal-Bahl, K Desai, B Stuart, ... Open Forum Infectious Diseases 9 (10), ofac435, 2022 | 3 | 2022 |
| Advocating for new patient-centered tools for value-based treatment choices in oncology JA Doshi, E Miller-Sonet, JT Puckett, HA Glick Journal of Clinical Pathways 5 (2), 44-47, 2019 | 3 | 2019 |
| Balancing affordability and access: lessons from new cholesterol-lowering drugs JA Doshi, JT Puckett, MS Parmacek, DJ Rader Health Affairs Forefront, 2018 | 3 | 2018 |
| Real-world adherence and discontinuation of oral antipsychotics and associated factors in a national sample of US Medicare beneficiaries with schizophrenia C Zacker, JT Puckett, S Kamal-Bahl ClinicoEconomics and Outcomes Research, 567-579, 2024 | 2 | 2024 |
| Real-World Survival, Healthcare Resource Utilization, and Costs Among US Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed … M Garg, J Puckett, S Kamal-Bahl, M Raut, KE Ryland, JA Doshi, ... Clinical Lymphoma Myeloma and Leukemia 24 (5), e181-e190, 2024 | 2 | 2024 |
| Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia SF Huntington, E de Nigris, J Puckett, S Kamal-Bahl, M Farooqui, ... Leukemia & Lymphoma 64 (14), 2286-2295, 2023 | 2 | 2023 |
| Real-world comparison of healthcare costs of venetoclax-obinutuzumab vs. Btki use among elderly US Medicare beneficiaries with chronic lymphocytic leukemia in the front-line … BS Manzoor, SF Huntington, D Jawaid, JT Puckett, N Emechebe, ... Blood 142, 5085, 2023 | 2 | 2023 |
| Assessing unmet need among elderly Medicare Beneficiaries with Mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costs P Squires, J Puckett, KE Ryland, S Kamal-Bahl, M Raut, JA Doshi, ... Leukemia & Lymphoma 64 (11), 1752-1770, 2023 | 2 | 2023 |
| Financial incentives tied to Medicare star ratings: impact on influenza vaccination uptake in Medicare beneficiaries. B Stuart, FE Loh, S Kamal-Bahl, J Vietri, D Bakken, J Puckett, JA Doshi American Journal of Managed Care 28 (6), 2022 | 2 | 2022 |
| 647: REAL-WORLD COMPARATIVE EFFECTIVENESS OF FIDAXOMICIN VS. VANCOMYCIN AMONG MEDICARE BENEFICIARIES WITH CLOSTRIDIOIDES DIFFICILE INFECTION ER Dubberke, JT Puckett, EN Obi, S Kamal-Bahl, K Desai, B Stuart, ... Gastroenterology 162 (7), S-157, 2022 | 2 | 2022 |
| Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton’s tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic … SF Huntington, BS Manzoor, D Jawaid, JT Puckett, N Emechebe, ... Journal of Managed Care & Specialty Pharmacy 30 (10), 1106-1116, 2024 | 1 | 2024 |
